Detalles de la búsqueda
1.
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Curr Oncol Rep
; 25(3): 189-199, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36705879
2.
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(11)2023 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37298380
3.
Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study.
Cancers (Basel)
; 16(10)2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38791970
4.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
J Thorac Oncol
; 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38461929
5.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Ther Adv Med Oncol
; 15: 17588359231198446, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37720499
6.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Eur J Cancer
; 195: 113404, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37948842
7.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov
; 13(7): 1556-1571, 2023 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068173
8.
Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
J Med Case Rep
; 15(1): 124, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33736690
Resultados
1 -
8
de 8
1
Próxima >
>>